Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review

Chen, Hanbo; Louie, Alexander V.; Boldt, Gabriel; Rodrigues, George; Palma, David A.; Senan, Suresh

doi:10.1016/j.cllc.2015.12.009

Cited by 58 publications

(47 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The QoL findings are consistent with those reported in individual SBRT and surgical studies, that is, HRQoL domains tend to be preserved after lung SBRT whereas HRQoL tends to decrease over the first postoperative year (3). The report's limitations are in keeping with the poor accrual to the primary study from which the data are drawn and in particular the very small patient numbers constrain the value of the authors' findings.…”

Section: Radiation Oncologysupporting

confidence: 87%

Early-Stage Lung Cancer, Surgery, and Stereotactic Body Radiation Therapy: Quality of Life

Videtic¹

2016

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Radiation Oncologysupporting

confidence: 87%

Early-Stage Lung Cancer, Surgery, and Stereotactic Body Radiation Therapy: Quality of Life

Videtic¹

2016

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Non‐small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide . With the development of radiotherapy, stereotactic ablative radiotherapy (SABR) has become an effective treatment for NSCLC . RTOG 0236 suggested that peripheral stage I non‐small cell tumors treated with SABR could achieve acceptable local control (LC) and overall survival (OS) .…”

Section: Introductionmentioning

confidence: 99%

“…1,2 With the development of radiotherapy, stereotactic ablative radiotherapy (SABR) has become an effective treatment for NSCLC. [3][4][5][6] RTOG 0236 suggested that peripheral stage I non-small cell tumors treated with SABR could achieve acceptable local control (LC) and overall survival (OS). 7 A phase 3 randomized trial comparing SABR with surgery has suggested that SABR was better tolerated and might lead to better OS compared with surgery for operable clinical stage I NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Background There is no consensus on the definition or recommended radiotherapy treatment of ultracentral non‐small cell lung cancer (NSCLC). Here, we report our institution's experience in treating ultracentral lung cancer patients with stereotactic ablative radiotherapy (SABR) of 60 Gy in eight fractions. Methods We retrospectively reviewed the outcomes of 21 ultracentral NSCLC patients treated with 60 Gy SABR in eight fractions. We defined ultracentral lung cancer as the planning target volume (PTV) directly abutting or overlapping central structures, including the proximal bronchial tree, heart, and great vessels but not the esophagus. The Kaplan‐Meier method was used to estimate overall survival (OS), progression‐free survival (PFS) and local control (LC). Toxicity was scored per the CTCAE v4.03. Results The median follow‐up time was 15 months, and the median OS was 15 months. The one‐ and two‐year OS rates were 87.5% and 76.6%, respectively. The one‐ and two‐year PFS rates were 71.1% and 64.0%, respectively. The one‐ and two‐year LC rates were 92.9% and 92.9%, respectively. The rate of grade 2 treatment‐related toxicities was 19.1%. There was no grade ≥ 3 treatment‐related toxicity. Conclusion SABR of 60 Gy in eight fractions is feasible for ultracentral NSCLC.

show abstract

“…Gamma Knife TM veya CyberKnife TM olarak da bilinen bu teknolojinin en büyük dezavantajı sadece büyük merkezlerde bulunması ve özel eğitimli personele ihtiyaç duymasıdır. SABR teknolojisinin küçük hücre dışı akciğer kanserli (KHDAK) hastalarda altın standart olarak kabul edilen cerrahi girişime alternatif olarak kullanılabilecek başarılı bir yöntem olduğu belirlenmiştir 8,9 . Profilaktik Kraniyel Radyoterapi/Işınlama (PCR/PCI) yöntemi özellikle küçük hücreli akciğer kanseri (KHAK) olan kişilerin tedavisinde etkin şekilde kullanılmaktadır.…”

Section: Radyoterapiunclassified

Current Modalities in Treatment of Cancer

Baykara¹

2016

BSBD

View full text Add to dashboard Cite

bsbd@balikesir.edu.tr www.bau-sbdergisi.com ÖZET Kanser, hücrelerin kontrolsüz bölünmesi ve çoğalması ile ortaya çıkan ve genetik ve çevresel koşulların etkisi altında olan kompleks bir hastalıktır. Bilinen 100'den fazla kanser türü olmasına ve belli tipteki kanserler için olabildiğince standart yaklaşımlar geliştirilmesine rağmen kanser aynı zamanda kişisel bir hastalıktır. Dünya üzerindeki hiçbir insanın DNA'sı birbirine benzemediği için kişilerin benzer tedavilere farklı cevaplar vermesi şaşırtıcı olmayan bir gerçektir. Teknolojinin ilerlemesi ile birlikte günümüzde var olan tedavilere ek olarak yeni tedavi yöntemleri geliştirilmektedir. Standart olarak kabul edilen kemoterapi, radyoterapi ve cerrahi yöntemlere ek olarak aşılar, biyolojik, hormonal, hedeflenmiş ve gen terapiler giderek artan sayıda kullanılmaya başlanmıştır. Kanser ve tedavisi hakkında bilgi edinmek isteyen bir kişinin karşısına farklı tedaviler, yaklaşımlar, bilimsel makaleler ve hurafelerden oluşan sonsuz bir kaynak denizi ortaya çıkmaktadır. Gerekli bilgiye ulaşmak için uzun ve detaylı araştırmalar yapmak gerekebilir. Bu derlemenin amacı çok basit veya çok karmaşık bilgiler arasında bir köprü oluşturmak, başarı ile uygulanan yöntemleri karşılaştırmak, günümüzde kullanılan tüm metodlar hakkında okuyucuya bilgi vermektir. Anahtar Kelimeler: Kanser tedavisi, gen terapi, radyoterapi, kemoterapi SUMMARYCancer is a complex disease emerging from uncontrolled cell proliferation and division due to various genetic and environmental factors. Even though standard procedures are applied to specific types of cancers, it is also a personal disease with more than 100 types. It is not surprising why every human being responses same to treatments as human DNA is unique. As technology progresses, new therapies including but not limited to biological, hormonal, targeted and gene therapies are developed besides current approaches such as chemotherapy, radiotherapy and surgery. One can easily get lost in a huge ocean of knowledge when he wants to learn about cancer as different types of treatments, approaches, scintific papers and superstitions are widely accesible through internet and it may take a while for the average person to reach the desired information. The aim of this review is to bridge over very simple or very complex information, compare the methods and inform the reader about modalities in cancer.

show abstract

Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review

Cited by 58 publications

References 31 publications

Early-Stage Lung Cancer, Surgery, and Stereotactic Body Radiation Therapy: Quality of Life

Early-Stage Lung Cancer, Surgery, and Stereotactic Body Radiation Therapy: Quality of Life

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer

Current Modalities in Treatment of Cancer

Contact Info

Product

Resources

About